PAD4 inhibitors like Cl-amidine, BB-Cl-amidine, and GSK484 not only suppress NET formation but also attenuate ovarian cancer metastasis, pointing to PAD4 as a central player in NET-driven pathologies [37]. This evidence concerns the gene PADI4 and ovarian carcinoma.